OTC : CSPHF

CStone Pharmaceuticals

$0.71 USD

$0 (0.0%)

Volume
1K
Average Volume
3.53K
Market Capitalization
$1.14B
P/E Ratio
-19.48
Dividend Yield
0.00%
Price Target
Year High
$1.01
Year Low
$0.60
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.18
Company Overview

OTC

Jianxin Yang

Biotechnology

Healthcare

CSPHF

136

CN

USD

https://www.cstonepharma.com

86 21 6033 5000

G2588M100

N/A

Liquidity Metrics

0.57

2.18

1.95

1.48

0.00

Sales & Valuation

$262.63M

26.71

9.70

-18.54

-0.24

Profitability

-$0.31

-$425.73M

-123.30%

-117.97%

-64.78%

-22.22%

P/E Metrics

-19.48

0.14

0.14

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Financial Health Scores

-3.54

2/9

$603.27M

$1.36B

$741.6M

-$384.67M

Key Metrics (TTM)

$6.05B

24.72

-22.76

2.18

-64.78%

-28.27%

-5.11%

-5.46%

149 days

Company Executives
Name Title
Jianxin Yang Chief Executive Officer, President of R&D and Executive Director
Qingmei Shi Senior Vice President & Chief Medical Officer
Qinzhou Qi VP and Head of R&D Management & Chief of Staff to the CEO
Yujuan La Senior Vice President of Product Development
Michael J. Choi Chief Business & Strategy Officer
Weicong Ni CFO & Company Secretary
Ying Hua Zhang Senior Vice President & Chief Operating Officer
Poll Results

No votes yet today — be the first to share your view!

About CStone Pharmaceuticals (OTC:CSPHF) Stock

CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents. These include Sugemalimab, a monoclonal antibody specifically targeting programmed death-ligand 1 (PD-L1); GAVRETO, an RET inhibitor prescribed for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumors that carry a PDGFRA exon 18 mutation. CStone's robust product pipeline features promisi ... ng candidates such as Nofazinlimab, a PD-1 antibody aimed at treating hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor developed for adults experiencing relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor also indicated for hepatocellular carcinoma. Further augmenting its development portfolio are various compounds including CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, all targeting solid tumors, alongside CS5001, which addresses both solid tumors and hematologic malignancies. Established in 2015, CStone Pharmaceuticals maintains its headquarters in Shanghai, China.

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

2026-06-25 05:44:00

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

2026-05-31 20:15:00

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low  population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients in this cohort.

Frequently Asked Questions

What is the current CStone Pharmaceuticals (CSPHF) stock price?

CStone Pharmaceuticals(OTC:CSPHF) stock price is $0.71 in the last trading session. During the trading session, CSPHF stock reached the peak price of $1.01 while $0.595 was the lowest point it dropped to. The percentage change in CSPHF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CSPHF stock was $0.

CSPHF's industry and sector of operation?

The OTC listed CSPHF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CSPHF?

Jianxin Yang | Chief Executive Officer, President of R&D and Executive Director
Qingmei Shi | Senior Vice President & Chief Medical Officer
Qinzhou Qi | VP and Head of R&D Management & Chief of Staff to the CEO
Yujuan La | Senior Vice President of Product Development
Michael J. Choi | Chief Business & Strategy Officer

How many employees does CSPHF have?

Number of CSPHF employees currently stands at 136. CSPHF operates from New Bund Times Square, Shanghai, SH 201203, CN.

Link for CSPHF official website?

Official Website of CSPHF is: https://www.cstonepharma.com

How do I contact CSPHF?

CSPHF could be contacted at phone #86 21 6033 5000 and can also be accessed through its website. CSPHF operates from New Bund Times Square, Shanghai, SH 201203, CN.

How many shares of CSPHF are traded daily?

The average number of CSPHF shares traded daily for last 3 months was 3.53K.

What is the market cap of CSPHF currently?

The market value of CSPHF currently stands at $1.14B with its latest stock price at $0.71